Search

ProQR Announces First Quarter 2021 Operating and Financial Results

Press release

Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini

May 06, 2021
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

Press release

Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development of the program ProQR

May 04, 2021
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

April 23, 2021
ProQR Announces Participation in Upcoming Kempen Life Sciences Conference

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 22, 2021
ProQR Announces Annual Meeting of Shareholders

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 20, 2021
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

April 13, 2021
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 05, 2021
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

April 02, 2021
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

March 31, 2021
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer

March 30, 2021